10-K: Iterum Therapeutics Outlines Share Structure and Regulatory Landscape in 10-K Filing

Iterum Therapeutics' 10-K filing details its share capital, regulatory environment, and strategic focus on its sulopenem program.

Summary

• Iterum Therapeutics has filed its annual 10-K report, detailing its share capital structure, regulatory environment, and strategic focus.
• The company's authorized share capital consists of 80,000,000 ordinary shares and 100,000,000 undesignated preferred shares, each with a par value of $0.01.
• A shareholder resolution passed on January 28, 2021, authorizes the board to issue new shares without shareholder approval until January 26, 2026.
• The company has opted out of statutory pre-emption rights for cash issuances, which also expires on January 26, 2026, and requires a 75% shareholder vote to renew.
• The document outlines various aspects of share issuance, dividends, repurchases, and shareholder meetings under Irish law.
• Iterum is focused on its sulopenem program, including both oral and IV formulations, targeting multi-drug resistant infections.
• The company expects to resubmit its NDA for oral sulopenem in the second quarter of 2024, with a potential FDA review completion in the fourth quarter of 2024.
• The company is also exploring strategic alternatives, including a potential sale or licensing of its sulopenem program.
• The company has completed a Phase 3 clinical trial (REASSURE) for oral sulopenem, demonstrating non-inferiority and superiority to Augmentin in the Augmentin-susceptible population.
• The company has completed additional non-clinical PK/PD investigations, as recommended by the FDA, which they believe support the dosing regimen selected for oral sulopenem.
• The company has a license agreement with Pfizer for sulopenem and its oral prodrug, with patents expiring between 2029 and 2041, subject to potential extensions.
• The company has QIDP and fast track designations for sulopenem and oral sulopenem for multiple indications.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has achieved positive clinical trial results and has a clear strategic direction, the financial risks and uncertainties surrounding its ability to continue as a going concern and raise capital are significant concerns.

Positives

• The company has completed a Phase 3 clinical trial (REASSURE) for oral sulopenem, demonstrating non-inferiority and superiority to Augmentin in the Augmentin-susceptible population.
• The company has completed additional non-clinical PK/PD investigations, as recommended by the FDA.
• The company has QIDP and fast track designations for sulopenem and oral sulopenem for multiple indications, which could provide additional market exclusivity.
• The company has a license agreement with Pfizer for sulopenem and its oral prodrug, with patents expiring between 2029 and 2041, subject to potential extensions.

Negatives

• The company's ability to raise additional capital through the issue of new shares for cash is limited to issuing only 1.8 million ordinary shares (or rights to acquire such shares) for cash, based on the amount of authorized ordinary shares unissued or unreserved and free from any statutory rights of pre-emption, and therefore available for issuance as of February 29, 2024.
• The company has opted out of pre-emption rights for cash issuances, requiring a 75% shareholder vote to renew by January 26, 2026.
• The company has incurred net losses in each year since its inception and anticipates that it will continue to incur significant losses unless it successfully commercializes its sulopenem program.
• The company is heavily dependent on the success of its sulopenem program, and its ability to develop, obtain marketing approval for and successfully commercialize oral sulopenem and sulopenem.

Risks

• The company's ability to raise additional capital through the issue of new shares for cash is limited to issuing only 1.8 million ordinary shares (or rights to acquire such shares) for cash, based on the amount of authorized ordinary shares unissued or unreserved and free from any statutory rights of pre-emption, and therefore available for issuance as of February 29, 2024.
• The company has opted out of pre-emption rights for cash issuances, requiring a 75% shareholder vote to renew by January 26, 2026.
• The company has incurred net losses in each year since its inception and anticipates that it will continue to incur significant losses unless it successfully commercializes its sulopenem program.
• The company is heavily dependent on the success of its sulopenem program, and its ability to develop, obtain marketing approval for and successfully commercialize oral sulopenem and sulopenem.
• The company has no experience in obtaining regulatory approval for a drug.
• Clinical trials of oral sulopenem, sulopenem or any other product candidate that the company may advance to clinical trials may fail to demonstrate safety and efficacy to the satisfaction of the FDA or comparable foreign regulatory authorities.
• Serious adverse events or undesirable side effects or other unexpected properties of oral sulopenem, sulopenem or any other product candidate may be identified during development or after approval.
• Even if a product candidate does obtain regulatory approval, it may never achieve the market acceptance by physicians, patients, hospitals, third-party payors and others in the medical community that is necessary for commercial success.
• The company currently has no commercial organization.
• The company's exploration and pursuit of strategic alternatives may not be successful.
• The company cannot predict whether bacteria may develop resistance to oral sulopenem or sulopenem.
• The company contracts with third parties for the manufacture of preclinical and clinical supplies and expects to continue to do so in connection with any future commercialization.
• The company relies heavily on the exclusive license agreement with Pfizer Inc., or Pfizer, for the patent rights and know-how required to develop and commercialize sulopenem etzadroxil and the know-how required to develop the IV formulation of sulopenem.
• If the company is unable to obtain and maintain patent protection or other intellectual property rights for oral sulopenem or its other technology and product candidates, or if the scope of the patent protection or intellectual property rights the company obtains is not sufficiently broad, the company may not be able to successfully develop or commercialize oral sulopenem or any other product candidates or technology or otherwise compete effectively in its markets.
• The volatility of the company's shares and shareholder base may hinder or prevent the company from engaging in beneficial corporate initiatives.

Future Outlook

The company expects to resubmit its NDA for oral sulopenem in the second quarter of 2024, with a potential FDA review completion in the fourth quarter of 2024. The company is also exploring strategic alternatives, including a potential sale or licensing of its sulopenem program.

Management Comments

• The board of directors determined that we should focus on a strategic process to sell, license, or otherwise dispose of our rights to sulopenem with the goal of maximizing shareholder value.
• We expect to resubmit our NDA to the FDA in the second quarter of 2024.
• We believe that sulopenem and oral sulopenem have the potential to be important new treatment alternatives to address growing concerns related to antibacterial resistance without the known toxicities of some of the most widely used antibiotics, specifically fluoroquinolones.

Industry Context

The document highlights the growing concern of antibiotic resistance and the need for new treatment options, positioning Iterum's sulopenem program as a potential solution. The document also references the FDA's concerns about fluoroquinolones, which are commonly used to treat UTIs, and the need for alternative treatments.

Comparison to Industry Standards

• The document mentions several competitors in the antibiotic space, including GlaxoSmithKline and Utility Therapeutics Limited, which are developing oral antibiotics for UTIs.
• The document also mentions several IV-administered products marketed for the treatment of infections resistant to first-line therapy for gram-negative infections, including Avycaz from AbbVie Inc. and Pfizer, Vabomere from Melinta Therapeutics, Inc., Zerbaxa from Merck & Co., Zemdri from Cipla, Xerava from Innoviva, Recarbrio from Merck & Co, and Fetroja from Shionogi & Co., Ltd.
• The document highlights that none of the most commonly used oral antibiotics for treatment of uUTIs were initially approved by the FDA within the last two decades, indicating a need for new treatment options.
• The document also notes that the Infectious Diseases Society of America and European Society for Microbiology and Infectious Diseases recommend against empiric use of fluoroquinolones for uUTIs, further highlighting the need for alternative treatments.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional capital and the volatility of its share price.
• Employees may be affected by potential changes in the company's strategy and operations, including potential layoffs or changes in compensation.
• Customers (physicians and patients) may benefit from the potential availability of new treatment options for multi-drug resistant infections.
• Suppliers and creditors may be affected by the company's financial situation and its ability to meet its obligations.

Next Steps

• The company expects to resubmit its NDA to the FDA in the second quarter of 2024.
• The company is exploring strategic alternatives, including a potential sale or licensing of its sulopenem program.
• The company may seek a commercial partner and/or directly commercialize oral sulopenem in the United States with a targeted sales force in the community setting, if approved by the FDA.
• The company may pursue development of its sulopenem program in additional indications in adults and children, including cUTIs, community acquired bacterial pneumonia, non-tuberculous mycobacterial pulmonary disease, cIAIs, bacterial prostatitis, gonorrhea, diabetic foot infection and bone and joint infection, as well as new formulations to support these indications.
• The company may seek to enhance its product pipeline through strategically in-licensing or acquiring clinical stage product candidates or approved products for the community and/or hospital and acute care markets.

Key Dates

Keywords

sulopenem, antibiotics, urinary tract infections, FDA, clinical trials, share capital, regulatory approval, patent, licensing, pre-emption rights